1 unknown. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Unknown 1 |
Follow Gangrene: new trials by email Literature Review of Gangrene trials Research Report on Gangrene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI) Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months - Critical Limb Ischemia | Phase 4 | Unknown | Leonardo Clavijo | 32 | 2020-02-24 | 2020-03-13 |
Chronic Limb-Threatening Ischemia (1) · Ischemia (1)
Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Necrosis (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Peripheral Arterial Disease (1) · Peripheral Vascular Diseases (1) · Vascular Diseases (1)
evolocumab (1)
Leonardo Clavijo (1)
United States (1)